Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma
NCT03087019Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in adenoid cystic carcinoma (ACC), sponsored by Dana-Farber Cancer Institute. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03087019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087019.